A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors

PURPOSE: Prolonged exposure of cancer cells to triapine, an inhibitor of ribonucleotide reductase, followed by gemcitabine enhances gemcitabine activity in vitro. Fixed-dose-rate gemcitabine (FDR-G) has improved efficacy compared to standard-dose. We conducted a phase I trial to determine the maximu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Mortazavi, Amir, Ling, Yonghua, Martin, Ludmila Katherine, Wei, Lai, Phelps, Mitch A., Liu, Zhongfa, Harper, Erica J., Ivy, S. Percy, Wu, Xin, Zhou, Bing-Sen, Liu, Xiyong, Deam, Deidre, Monk, J. Paul, Hicks, William J., Yen, Yun, Otterson, Gregory A., Grever, Michael R., Bekaii-Saab, Tanios
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646991/
https://ncbi.nlm.nih.gov/pubmed/22847785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9863-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares